PXS-5505A is under clinical development by Syntara and currently in Phase I for Scar. According to GlobalData, Phase I drugs for Scar does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PXS-5505A LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PXS-5505A overview

PXS-5505A is under development for the treatment of myelofibrosis, kidney fibrosis, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML), lung fibrosis, liver cancer, cholangiocarcinoma (CCA), pancreatic ductal adenocarcinoma, primary myelofibrosis, post polycythemia vera (PV) myelofibrosis, post-essential thrombocythemia (ET) myelofibrosis and prevention of scars. It is administered through oral route in the form of capsule. The drug candidate acts by targeting lysyl oxidase (LOX), LOX1, LOX2, LOX3 and LOX4 and is being developed based on amine oxidase platform technology.

It was also under development for the treatment of melanoma, malignant mesothelioma, glioblastoma multiforme (GBM), liver fibrosis and fibrosis and head and neck cancer and metastatic hepatocellular carcinoma.

Syntara overview

Syntara, formerly Pharmaxis, is a clinical-stage drug development company. It develops drugs for inflammatory, fibrotic and selected cancer indications diseases. The company product pipeline comprises of PXS-5505, PXS-5382, PXS-6302, PXS-4728, PXS-4699 and PXS-5370. Syntara therapeutic areas include myelofibrosis, liver and pancreatic cancer, pulmonary fibrosis, anti-fibrotic, IPF, CKD and NASH, anti-scarring, burns, established scars, isolated rapid eye movement sleep behavior disorder (IRBD), Parkinson’s disease, anti-inflammatory and multiple indications. The company provides orbital dry powder inhalers. It sells its products under the brands Bronchitol and Aridol. Syntara is headquartered in Sydney, French Forest, Australia.

For a complete picture of PXS-5505A’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.